ADReCS

Pharmaceutical Information

Drug Name	Imatinib
Drug ID	BADD_D01136
Description	Imatinib is a small molecule kinase inhibitor used to treat certain types of cancer. It is currently marketed by Novartis as Gleevec (USA) or Glivec (Europe/Australia) as its mesylate salt, imatinib mesilate (INN). It is occasionally referred to as CGP57148B or STI571 (especially in older publications). It is used in treating chronic myelogenous leukemia (CML), gastrointestinal stromal tumors (GISTs) and a number of other malignancies. It is the first member of a new class of agents that act by inhibiting particular tyrosine kinase enzymes, instead of non-specifically inhibiting rapidly dividing cells.
Indications and Usage	For the treatment of Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML), Ph+ acute lymphoblastic leukaemia, myelodysplastic/myeloproliferative diseases, aggressive systemic mastocytosis, hypereosinophilic syndrome and/or chronic eosinophilic leukemia (CEL), dermatofibrosarcoma protuberans, and malignant gastrointestinal stromal tumors (GIST).
Marketing Status	approved
ATC Code	L01EA01
DrugBank ID	DB00619
KEGG ID	D08066
MeSH ID	D000068877
PubChem ID	5291
TTD Drug ID	D0AZ3C
NDC Product Code	63850-4826; 68554-0034; 43598-345; 65162-795; 42292-044; 0378-2246; 43598-344; 51407-270; 0378-2245; 42292-043; 51407-269; 48087-0143; 65162-794
UNII	BKJ8M8G5HI
Synonyms	Imatinib Mesylate \| Mesylate, Imatinib \| Imatinib Methanesulfonate \| Methanesulfonate, Imatinib \| STI571 \| STI-571 \| STI 571 \| Gleevec \| Glivec \| ST 1571 \| ST1571 \| CGP 57148 \| CGP57148B \| CGP-57148 \| CGP57148 \| Imatinib \| Alpha-(4-methyl-1-piperazinyl)-3'-((4-(3-pyridyl)-2-pyrimidinyl)amino)-p-tolu-p-toluidide

Chemical Information

Molecular Formula	C29H31N7O
CAS Registry Number	152459-95-5
SMILES	CC1=C(C=C(C=C1)NC(=O)C2=CC=C(C=C2)CN3CCN(CC3)C)NC4=NC=CC(=N4)C5=CN=CC=C5
Chemical Structure

ADRs Induced by Drug

*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..

ADR Term	ADReCS ID	ADR Frequency (FAERS)	ADR Severity Grade (FAERS)	ADR Severity Grade (CTCAE)
Abdominal mass	07.01.01.003	0.000168%		Not Available
Acanthosis	23.01.04.003	0.000112%		Not Available
Adenocarcinoma gastric	16.13.03.002; 07.21.02.002	0.000280%		Not Available
Adenocarcinoma of colon	16.13.01.010; 07.21.01.008	0.000224%		Not Available
Alopecia scarring	23.02.02.009	0.000168%		Not Available
Atonic seizures	17.12.03.020	0.000112%		Not Available
Bladder transitional cell carcinoma	20.03.04.003; 16.08.01.002	0.000336%		Not Available
Blood blister	23.03.01.028; 12.01.06.013	0.001164%		Not Available
Breast cancer recurrent	21.05.01.017; 16.10.01.009	0.000112%		Not Available
Bronchial carcinoma	22.08.01.015; 16.19.02.004	0.000168%		Not Available
Cervical cyst	21.06.02.006; 16.04.05.002	0.000112%		Not Available
Chloroma	16.01.08.003; 01.10.08.003	0.000336%		Not Available
Chordoma	16.29.01.002; 15.09.03.013	0.000951%		Not Available
Chronic lymphocytic leukaemia refractory	16.01.06.004; 01.10.06.004	0.000112%		Not Available
Chronic respiratory failure	22.02.06.005; 14.01.04.005	0.000224%		Not Available
Colon cancer stage IV	16.13.01.014; 07.21.01.012	0.000112%		Not Available
Concomitant disease aggravated	08.01.03.063	0.000526%		Not Available
Hypergammaglobulinaemia benign monoclonal	16.23.01.004; 01.14.01.004	0.000112%		Not Available
Leiomyosarcoma	16.33.07.001; 15.09.03.016	0.000112%		Not Available
Lichen sclerosus	23.03.08.006; 21.10.03.010	0.000280%		Not Available
Lung adenocarcinoma	22.08.01.007; 16.19.01.002	0.000280%		Not Available
Metastases to adrenals	05.01.04.007; 16.22.02.012	0.000112%		Not Available
Metastases to bone	16.22.02.005; 15.09.03.006	0.000672%		Not Available
Metastases to kidney	16.22.02.017; 20.01.04.010	0.000168%		Not Available
Metastases to lymph nodes	16.22.02.006; 01.09.01.015	0.000783%		Not Available
Metastases to skin	16.22.02.023; 23.07.04.026	0.000168%		Not Available
Neonatal respiratory distress syndrome	22.11.02.010; 18.04.10.003	0.000168%		Not Available
Neuroblastoma	17.20.03.002; 16.30.03.002; 05.01.04.001	0.000224%		Not Available
Normal newborn	18.08.06.001	0.000716%		Not Available
Obstruction gastric	07.13.04.002	0.000112%

The 28th Page First Pre 28 29 30 31 32 Next Last Total 32 Pages